AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Charles River Laboratories and Fios Genomics Form a Strategic Alliance to Provide Bioinformatics-driven Drug Discovery and Safety Assessment

January 16, 2020 GMT

WILMINGTON, Mass. & EDINBURGH, Scotland--(BUSINESS WIRE)--Jan 16, 2020--

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Fios Genomics, a leading provider of bioinformatics data analysis services.

Access to high quality, transparent bioinformatics presents a challenge for many drug development teams. Compiling disparate, complex data file types into single datasets for interpretation requires a rigorous assessment of data quality, as well as an analytical approach that emphasizes biological relevance and the assessment of statistical significance.

Through this partnership, Charles River clients will have access to Fios Genomics’ expertise in bioinformatics, statistics and biology to assist in the sourcing and analysis of the high-dimensional, multi-variant datasets associated with drug development including microarrays, next-generation sequencing (NGS), proteomics, metabolomics and epigenetics as well as the associated meta-data.

The biologically-relevant insights revealed by the team at Fios Genomics, combined with Charles River’s streamlined integrated drug discovery and development platform and the scientific expertise of both organizations, will enable Charles River clients to make more data-driven decisions about their programs, improving both confidence and speed.

Approved Quotes

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Fios Genomics

Fios Genomics provide a wide range of bioinformatics analysis services, supporting drug discovery and development and applied research across all species. Using the best in class tools and methods, Fios provide a functional and interactive reporting architecture, allowing scientists to fully explore their data. We can analyse ’omics data in combination with other outputs from experiments or trials such as imaging data and clinical information. This helps to build up the data picture while ensuring that a robust analysis is delivered. To learn more about our capabilities, visit www.fiosgenomics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200116005432/en/

CONTACT: Investor Contact:

Todd Spencer

Corporate Vice President, Investor Relations

781-222-6455

todd.spencer@crl.comMedia Contact:

Charles River

Amy Cianciaruso

Corporate Vice President, Public Relations

781-222-6168

amy.cianciaruso@crl.comFios Genomics

Callum Spreng

Managing Director, Spreng Thomson

+44 (0)141 548 5191

Callum@sprengthomson.com

KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: DATA MANAGEMENT BIOTECHNOLOGY TECHNOLOGY OTHER HEALTH HEALTH GENERAL HEALTH PHARMACEUTICAL MEDICAL DEVICES RESEARCH GENETICS SCIENCE

SOURCE: Charles River Laboratories International, Inc.

Copyright Business Wire 2020.

PUB: 01/16/2020 08:00 AM/DISC: 01/16/2020 08:01 AM

http://www.businesswire.com/news/home/20200116005432/en